Stockreport

Cullinan Therapeutics Provides Corporate Update and Highlights Anticipated 2026 Milestones

Cullinan Oncology, Inc.  (CGEM) 
PDF Data readouts planned for CLN-978 across all three autoimmune indications in 2026, including single dose and repeat dosing data Company to complete monotherapy expans [Read more]